Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: the role of rituximab
- 3 December 2010
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 50 (12) , 2753-2760
Abstract
Idiopathic thrombotic thrombocytopenic purpura–hemolytic uremic syndrome (TTP‐HUS) is a rare disease responsive to treatment with plasma exchange (PE) but with a high percentage of relapse or refractory patients. A severe deficiency of ADAMTS‐13 (<5% of normal activity), congenital or caused by an autoantibody, may be specific for TTP and it has been proposed that severe ADAMTS‐13 deficiency now defines TTP. B cells play a key role in both the development and the perpetuation of autoimmunity, suggesting that B‐cell depletion could be a valuable treatment approach for patients with idiopathic TTP‐HUS. This review of the literature focuses on the role of rituximab, a chimeric monoclonal antibody directed against CD20 antigen expressed by B lymphocytes, in patients with relapsing or refractory TTP‐HUS with or without ADAMTS‐13 deficiency, suggesting that rituximab may produce clinical remission in a significant proportion of patients. Rituximab therapy reduces plasma requirement and avoids complications related to salvage‐immunosuppressive therapy. In conclusion, rituximab provides an effective, well‐tolerated, and safe treatment option for patients with idiopathic TTP‐HUS, thus giving an alternative approach to the current treatment based on PE.Keywords
This publication has 63 references indexed in Scilit:
- ADAMTS13 activity in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patientsBlood, 2003
- How I treat patients with thrombotic thrombocytopenic purpura–hemolytic uremic syndromeBlood, 2000
- Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndromeThe American Journal of Medicine, 1999
- Therapeutic Plasma Exchange: An Update from the Canadian Apheresis GroupAnnals of Internal Medicine, 1999
- Thrombotic thrombocytopenic purpura: Evolution across 15 yearsJournal of Clinical Apheresis, 1996
- Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemicBlood, 1992
- Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchangeTransfusion, 1992
- Improved Survival in Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic SyndromeNew England Journal of Medicine, 1991
- Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 1991
- THROMBOTIC THROMBOCYTOPENIC PURPURAMedicine, 1966